STOCK TITAN
  1. Home
  2. News
  3. GILD

Gilead Sciences Inc - GILD STOCK NEWS

Welcome to our dedicated page for Gilead Sciences news (Ticker: GILD), a resource for investors and traders seeking the latest updates and insights on Gilead Sciences stock.

Gilead Sciences, Inc. is an American biopharmaceutical company based in Foster City, California. The company specializes in researching, developing, and marketing antiviral drugs used in the treatment of a variety of viral infections including HIV/AIDS, hepatitis B and C, influenza, and COVID-19. Gilead is renowned for its innovative approach to creating life-saving therapies, with a core focus on diseases such as HIV and hepatitis. Some of its groundbreaking products include ledipasvir/sofosbuvir and sofosbuvir, pivotal in the treatment of hepatitis C.

Gilead's extensive portfolio has been significantly enhanced through strategic acquisitions. The purchase of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga has allowed the company to diversify into pulmonary and cardiovascular diseases and cancer treatments. The acquisition of Pharmasset was particularly notable, providing Gilead with the rights to the hepatitis C drug Sovaldi, further combined into the drug Harvoni. Additionally, Gilead has expanded its oncology offerings through the acquisitions of Kite, Forty Seven, and Immunomedics, strengthening its position in both cell therapy and non-cell therapy in oncology.

Gilead continually seeks to innovate and push the boundaries of medicine to offer better therapeutic solutions. Recent projects include expanding its antiviral pipeline and exploring novel treatments for various cancers. Financially, Gilead remains robust, with substantial investments in research and development to drive future growth and maintain its leadership in the biopharmaceutical industry.

News

Gilead Named Number One Overall Philanthropic Funder of HIV-Related Programs for Second Year in a Row by Funders Concerned About AIDS

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq:GILD) - Gilead Recognized as Top Funder of Health Equity Programs for BIPOC and LGBTQ+ Communities
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.28%
Tags
none
-
News

Gilead Sciences: Research Scholars Program Scientists Advancing HIV Research

Rhea-AI Summary
Gilead Sciences: Research Scholars Program Supports Early-Career Investigators Focused on Advancing Scientific Knowledge in HIV Research, Fueling HIV Research Through the Program, Addressing Unmet Needs in HIV Research
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
none
-
News

Gilead Sciences to Present at Upcoming Investor Conferences

Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) executives to speak at investor conferences. Live webcasts and replays available on investors.gilead.com. Key SEO terms: Gilead Sciences, investor conferences, webcasts, replays, GILD stock, Jefferies London Healthcare Conference, Evercore ISI HealthCONx Conference, Piper Sandler Healthcare Conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.75%
Tags
conferences
News

Gilead Sciences Announces Third Quarter 2023 Financial Results

Rhea-AI Summary
GILD: Gilead Sciences, Inc. Announces 5% Increase in Product Sales Excluding Veklury and 12% Increase in Biktarvy Sales in Q3 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.36%
Tags
earnings
-
News

Gilead Sciences: Advancing Global Health Equity in Tropical Regions

Rhea-AI Summary
Gilead Sciences has been working to revolutionize the treatment of visceral leishmaniasis, a widespread and deadly parasitic disease, through a long-term partnership with Dr. Shyam Sundar. The company has made significant progress in developing innovative clinical management approaches and providing support for better treatment access and screening in endemic regions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
News

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers

Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce promising results from the Phase 2 EDGE-Gastric study, showing encouraging overall response rate (ORR) and six-month progression-free survival (PFS) rate in patients with gastric, gastroesophageal junction, or esophageal adenocarcinoma. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. Six-month PFS rates were 93% and 68% for PD-L1-high and PD-L1-low tumors, respectively. Detailed results will be presented at the ASCO Monthly Plenary Series.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
News

Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers

Rhea-AI Summary
Gilead Sciences and Arcus Biosciences announce positive results from the Phase 2 EDGE-Gastric study, showing promising overall response rate (ORR) and six-month progression-free survival (PFS) rate. Domvanalimab plus zimberelimab and chemotherapy demonstrated an ORR of 80% in patients with PD-L1-high tumors and 46% in patients with PD-L1-low tumors. The six-month PFS rate was 93% for PD-L1-high tumors and 68% for PD-L1-low tumors. The regimen was well tolerated with a similar safety profile to anti-PD-1 plus chemotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.65%
Tags
none
-
News

Gilead to Present Late Breaking Data and Real World Evidence Highlighting Key Hepatitis Indications at The Liver Meeting® 2023

Rhea-AI Summary
Gilead Sciences announces new viral hepatitis data presented at AASLD The Liver Meeting®. Key findings include primary endpoint results from the Phase 2b MYR204 study evaluating Hepcludex® (bulevirtide) in combination with pegylated interferon alfa-2a (PegIFNα) in patients with chronic hepatitis delta virus (HDV), and an integrated analysis of Week 96 data from pivotal Phase 2b and Phase 3 studies evaluating the efficacy and safety of bulevirtide monotherapy. Long-term results from studies of Vemlidy® (tenofovir alafenamide, TAF) in chronic hepatitis B (HBV) will also be presented.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.44%
Tags
conferences
-
News

Gilead and Kite Oncology Present Data Demonstrating Car T-cell Therapy Survival Benefit and Showcasing Latest Advances in Blood Cancer Portfolio at ASH 2023

Rhea-AI Summary
Gilead Sciences and Kite, a Gilead Company, will present 29 presentations at the 65th American Society of Hematology (ASH) Annual Meeting. Key presentations include three-year results from ZUMA-12 investigating CAR T-cell therapy, post-hoc analyses showing the curative intent of Yescarta, and real-world evidence studies for Tecartus. New clinical data from the Phase 1 study of CART-ddBCMA in patients with multiple myeloma will also be featured.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.3%
Tags
none
News

Gilead's Commitment to Advancing Health Equity for Black Women and Ending the HIV Epidemic

Rhea-AI Summary
Gilead, a biopharmaceutical company, is committed to health equity and addressing the needs of communities with the greatest unmet needs. The company focuses on supporting and advocating for Black women and girls, who are disproportionately affected by disease. Gilead recently participated in the U.S. Conference on HIV/AIDS, where the theme was 'A Love Letter to Black Women'. Black women account for 54% of new HIV diagnoses among women aged 16 and older, despite comprising only 14% of the population. However, they are underrepresented in HIV clinical trials due to barriers like stigma, medical distrust, and limited access to trial study sites.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.99%
Tags
none

FAQ

What is the current stock price of Gilead Sciences (GILD)?

The current stock price of Gilead Sciences (GILD) is $90.19 as of November 22, 2024.

What is the market cap of Gilead Sciences (GILD)?

The market cap of Gilead Sciences (GILD) is approximately 111.8B.

What is Gilead Sciences, Inc.?

Gilead Sciences is an American biopharmaceutical company that focuses on developing antiviral drugs for diseases like HIV, hepatitis B and C, influenza, and COVID-19.

Where is Gilead Sciences headquartered?

Gilead Sciences is headquartered in Foster City, California.

What are some key products of Gilead Sciences?

Some key products include ledipasvir/sofosbuvir and sofosbuvir for hepatitis C treatment and several innovative antiviral therapies.

Which companies has Gilead Sciences acquired?

Gilead has acquired companies such as Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, Calistoga, Pharmasset, Kite, Forty Seven, and Immunomedics.

What diseases does Gilead Sciences' portfolio cover?

Gilead's portfolio covers life-threatening diseases like HIV, hepatitis B and C, pulmonary and cardiovascular diseases, influenza, and various cancers.

How has Gilead expanded its oncology offerings?

Gilead has bolstered its oncology portfolio through acquisitions of Kite, Forty Seven, and Immunomedics, enhancing its cell therapy and non-cell therapy options.

What is Gilead's financial condition?

Gilead maintains a strong financial position with significant investments in research and development to support ongoing growth and innovation.

What is Gilead's approach to research and development?

Gilead focuses on continual innovation and investment in R&D to develop groundbreaking treatments for viral infections and other serious diseases.

What recent projects is Gilead working on?

Gilead is currently working on expanding its antiviral drug pipeline and exploring new treatments for various types of cancer.

Where can I find the latest news about Gilead Sciences?

You can find the latest updates and news about Gilead Sciences on their official website and through reliable financial news sources.

Stock GILD logo
Gilead Sciences Inc

NYSE:GILD

GILD Rankings

#114 Ranked by Market Cap
#873 Ranked by Dividends

GILD Stock Data

111.79B
1.24B
0.12%
88.41%
1.42%
Drug Manufacturers - General
Biological Products, (no Disgnostic Substances)
Link
United States of America
FOSTER CITY